Company intelligence / Profile preview

RespiVert

Ownership: Private
Development stage: Phase 1

Overview

RespiVert developed a pipeline of novel, narrow spectrum kinase inhibitors as first-in-class inhaled therapies for severe pulmonary diseases. Lead compounds RV‑568 and RV‑1088 targeted asthma, COPD, and cystic fibrosis. The company was acquired by Centocor Ortho Biotech (Johnson & Johnson) in June 2010 while its lead programs were entering early-stage clinical development. The scientific team and discovery platforms were retained post-acquisition to continue research in London.

Therapeutic areas: PulmonologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

RV-568

Phase 1

Indications: Asthma, Chronic obstructive pulmonary disease, Cystic fibrosis

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on RespiVert.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RespiVert.

Explore the full profile